Abstract

Fever is frequently the only clinical sign of infection in patients with chemo-induced neutropenia. In this setting, empirical administration of broad spectrum antibiotics must be rapid. The aim of this work was to compare, for the first time, cefpirome (CPO) and piperacillin-tazobactam (FT) in a large randomized trial. Two hundred-eight febrile neutropenic episodes (FNE) (≥ 38,5°C and ANC < 0.5 giga/1) were treated by randomization, as first line therapy, using either CPO 2 g × 2/day (105 cases) or FT 4 g × 3/day (103 cases), alone (CPO: 15/PT: 15), or plus aminoglycoside (165 cases, CPO: 82/PT: 83) or quinolone (CPO: 2/PT: 2). There were 131 men and 77 women aged between 17 and 83 years (median: 49) who received chemotherapy (n=160) or allogeneic (n=10) or autologous (n=38) stem cell transplantations. Underlying diseases were: acute leukemia (n=131), lymphoma (n=33), myeloma (n=16), solid tumor (n=8), myeloproliferative disorder (n=9), chronic lymphoid leukemia (n=5), aplastic anemia (n=3), myelodysplasia (n=3). Distribution of age, neutropenia duration (median: 17 days), underlying disease, and protocol therapy duration (median: 11 days) was comparable in both arms. A rnicrobiologically documented infection (MDI) was evidenced in 57 cases (27%). Bacteria were isolated from blood cultures in 54 cases (Gram positive: 32 cases). Their in vitro susceptibility rates to CPO and FT were not different. Two days after antibiotics initiation, clinical (fever disappearance) and microbiological (culture negativation) success rates (SR) were 62% for CPO versus 61% for FT and 50% versus 55% respectively in case of MDI (p = 0.89). Two deaths and 77 failures were registered. At the end of protocol, SR (no antibiotic change/absence of superinfection) was 59% with CPO versus 50% with FT (p = 0.27) and 53% versus 40% respectively in the 151 cases with neutropenia ≥ 10 days (p = 0.17). The occurrence of side effects was similar in both arms. In our hands, the efficacy of CPO and FT was comparable for treating FNE.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call